Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 11

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 11
---
 the sale of our common stock in the aggregate amount of $48.0 million at an assumed offering price of $40.61 per share, the last reported sale price of our common stock on Nasdaq Capital Market as of July 14, 2025, and after deducting estimated offering commissions and expenses payable by us, our net tangible book value as of March 31, 2025 would have been $26.2 million, or $5.05 per share of common stock. This represents an immediate increase in the net tangible book value of $10.55 per share to our existing stockholders and an immediate and substantial dilution in net tangible book value of $35.56 per share to new investors. The following table illustrates this per share dilutions:

| Assumed offering price per share                                   
 Net tangible book value per share as of March 31, 2025             |     |     | (5.50 | ) |     |   | 40.61 |
|:-------------------------------------------------------------------|:----|:----|------:|:--|:----|:--|------:|
| Increase in net tangible book value per share after this offering  |     |     | 10.55 |   |     |   |       |
| As-Adjusted net tangible book value per share as of                
 July 11, 2025, after giving effect to this offering                |     |     |       |   |     |   |  5.05 |
| Dilution per share to new investors participating in this offering |     |     |       |   |     | $ | 35.56 |

The above discussion and table exclude:

| • |     | 884,371 shares of common stock issuable upon exercise of the options granted to employees and non-employees, as well as options granted to members of the board of directors, at a weighted-average exercise price of $17.76 per share, as of March 31, 2025; |

| • |     | 89,676 shares of common stock issuable upon vesting of non-vested stock 
 granted to employees, consultants and directors, as of March 31, 2025;  |

| • |     | 173,492 shares of common stock reserved for issuance under our 2021 Employee Stock Purchase Plan, as of 
 March 31, 2025; and                                                                                     |

To the extent any of these outstanding options or warrants are exercised at a price less than